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Background—Ischemia followed by reperfusion (I/R) causes apoptosis, inflammation, and tissue damage leading to organ
malfunction. Ischemic preconditioning can protect against such injury. This study investigates the contribution of the
acute phase proteins a1-acid glycoprotein (AGP) and a1-antitrypsin (AAT) to the protective effect of ischemic
preconditioning in the kidney.
Methods and Results—Exogenous AGP and AAT inhibited apoptosis and inflammation after 45 minutes of renal I/R in
a murine model. AGP and AAT administered at reperfusion prevented apoptosis at 2 hours and 24 hours, as evaluated
by the presence of internucleosomal DNA cleavage, terminal deoxynucleotidyl transferase–mediated dUTP nick
end-labeling, and the determination of renal caspase-1– and caspase-3–like activity. AGP and AAT exerted
anti-inflammatory effects, as reflected by reduced renal tumor necrosis factor-a expression and neutrophil influx after
24 hours. In general, these agents improved renal function. Similar effects were observed when AGP and AAT were
administered 2 hours after reperfusion but to a lesser extent and without functional improvement. Moreover, I/R elicited
an acute phase response, as reflected by elevated serum AGP and serum amyloid P (SAP) levels after 24 hours, and
increased hepatic acute phase protein mRNA levels after 18 hours of renal reperfusion.
Conclusions—We propose that the antiapoptotic and anti-inflammatory effects of AGP and AAT contribute to the delayed
type of protection associated with ischemic preconditioning and other insults. This mechanism is potentially involved
in the course of many clinical conditions associated with I/R injury. Moreover, exogenous administration of these
proteins may provide new therapeutic means of treatment. (Circulation. 2000;102:1420-1426.)
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Prolonged ischemia followed by reperfusion (I/R) inducesapoptosis and inflammation, leading to organ dysfunction
and tissue damage. We recently demonstrated that acute
primary apoptosis during early reperfusion is crucial to the
initiation of reperfusion-induced inflammation.1 Conversely,
the central inflammatory mediator, tumor necrosis factor-a
(TNF-a), was shown to contribute to late apoptosis in the
course of renal I/R.2
TNF-a is also an inducer of the acute phase response (APR),
a complex series of reactions executed by the host in the
immediate aftermath of injury, trauma, or infection.3 Protection
against reperfusion injury can be induced by various means,
including antecedent administration of endotoxin,4–6 heat
shock,7 and single or multiple periods of brief antecedent
ischemia.8 Besides such protection, the latter treatments are all
expected to induce an APR.3,9 During the APR, liver cells and
various epithelial cells respond to increasing levels of, among
others, TNF-a by producing acute phase proteins, including
a1-acid glycoprotein (AGP) and a1-antitrypsin (AAT).10 These 2
major acute phase proteins exhibit various anti-inflammatory
effects11–13 and have been shown to prevent hepatocyte apopto-
sis in a model of TNF-a/galactosamine toxicity.14
The present study investigates whether AGP and AAT can
reduce I/R-induced apoptosis and inflammation and whether
renal I/R induces an APR. The results show that physiological
serum levels of exogenous AGP and AAT strongly reduce
apoptosis and inflammation after I/R and that renal I/R
induces an APR.
Methods
Antibodies and Reagents
Anti-murine neutrophil monoclonal antibody (mAb) Gr-1 was ob-
tained from Pharmingen; rabbit anti-murine AGP polyclonal anti-
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bodies were kindly provided by Dr P. Heegaard (Danish Veterinary
Laboratory, Copenhagen, Denmark); peroxidase-conjugated goat
anti-rat and peroxidase-conjugated goat anti-rabbit IgGs were from
Jackson; peroxidase-conjugated and alkaline phosphatase–conju-
gated sheep anti-digoxigenin and digoxigenin 11-dUTP were from
Boehringer-Mannheim; peroxidase-conjugated rabbit anti-sheep IgG
was from DAKO; rabbit anti-murine serum amyloid P (SAP) and
SAP standard were from Calbiochem-Novabiochem; and Ac-
YVAD-amc and Ac-DEVD-amc were from the Peptide Institute. All
other reagents were purchased from Sigma Chemical Co.
Experimental Protocol
Male Swiss mice weighing 20 to 25 g from Charles River Breeding
Laboratories (Heidelberg, Germany) were housed individually in
standard cages with access to food and water ad libitum. The studies
were approved by the Institutional Animal Care Committee of the
University of Maastricht. Forty-five minutes of unilateral ischemia
of the left kidney was followed by contralateral nephrectomy, as
described in detail previously.2 The animals were euthanized at
indicated time points. At the time of euthanization, blood was
collected by orbital puncture, and the left kidney was harvested.
At reperfusion, mice were administered intraperitoneally (IP) 5
mg bovine AGP (n512) or 0.5 mg human AAT (n512) in 0.5 mL
sterile PBS, resulting in serum levels identical to those observed
during the APR.10 In separate groups, mice received AGP (n58) or
AAT (n58) after 2 hours of reperfusion. To further delineate the
therapeutic efficacy of AGP treatment, mice received 1.7 mg AGP
(n53), 0.5 mg AGP (n53), and 0.17 mg AGP (n53) in 0.5 mL PBS
at reperfusion and were euthanized after 2 hours. A control group
received vehicle consisting of 0.5 mL PBS IP (n510). A sham-
operated group (n512) was subjected to the same surgical procedure
without clamping of the renal pedicle, treated with PBS, and
euthanized at corresponding time points.
In an experiment to investigate whether renal I/R induced an APR,
mice were subjected to renal I/R, and blood was collected by orbital
puncture at 8, 16, and 24 hours after ischemia (n512). Additional
animals received 30 mg IP lipopolysaccharide (LPS, Escherichia coli
serotype O55:B5) (n53) or 0.5 mL of PBS IP (n53) and served,
respectively, as positive and negative controls for the development of
an APR.
Apoptosis Assays
Presence of internucleosomal DNA cleavage in kidneys was inves-
tigated with a commercial ligase-mediated polymerase chain reaction
assay kit (Apoalert, Clontech) according to the manufacturer’s
instructions. Renal caspase-1– and caspase-3–like activities were
assessed as described15 by measuring the release of fluorescent
7-amino-4-methylcoumarin for 1 hour after incubating renal lysates
with the fluorogenic substrate Ac-YVAD-amc (caspase-1–like) or
Ac-DEVD-amc (caspase-3–like).
MPO, BUN, and Serum Creatinine
Renal neutrophil accumulation was quantified by measuring renal
myeloperoxidase (MPO) content as described.2 MPO activity is
expressed per milligram tissue by comparing the optical density of
samples with a horseradish peroxidase titration curve and standard-
ized with respect to wet/dry ratios. Blood urea nitrogen (BUN)
content and serum creatinine levels were measured in serum by using
a BUN Unimate 5 kit and a CREA MPR3 kit (Boehringer-
Mannheim) in a Cobas Fara autoanalyzer (Roche).
Histology
Kidney specimens were immediately frozen and stored at 270°C or
fixed in buffered formalin and embedded in paraffin. Frozen sections
(5 mm) were stained for neutrophils with mAb Gr-1 as described.1
Immunostaining for TNF-a with digoxigenin-labeled mAb 52B83
was performed on paraffin sections as described.2 Histological
aspects of apoptosis were studied by standard terminal deoxynucleo-
tidyl transferase–mediated dUTP nick end-labeling (TUNEL) as
described.16
SAP ELISA and Single Radial Immunodiffusion
for Serum AGP
Serum SAP was measured by use of a sandwich ELISA. A 96-well
Immunomaxisorp plate (Nunc) was coated with a rabbit anti-mouse
SAP IgG. Aspecific binding was blocked with BSA; after washing
procedures, samples were diluted, and a standard titration curve of a
known quantity of murine SAP was obtained. Detection was per-
formed by use of a biotinylated rabbit anti-mouse SAP IgG, followed
by incubation with substrate. Serum AGP levels were determined by
single radial immunodiffusion17 with use of agar gels containing 5%
anti-AGP serum. Because purified murine AGP was not readily
available, the obtained results were calibrated against a dilution of
murine plasma obtained 36 hours after pretreatment with 30 mg LPS,
which also served as a positive control.
Measurement of Hepatic Acute Phase Protein
mRNA Content
Total RNA was extracted from livers and transcribed into cDNA, of
which the concentration was subsequently standardized on the basis
of the b-actin cDNA fraction. To determine hepatic AGP, AAT, and
SAP mRNA content, three 2-fold serial dilutions of cDNA were
amplified with specific primers. Murine AGP mRNA–specific prim-
ers, designed on the basis of sequence homology with an acute
phase–inducible gene in Mus caroli,18 were sense primer 59-
GCGGCTGTCCTAAACCCT-39 and antisense primer 59-
CAAGTCAAAGGCAAGCATG-39; murine AAT mRNA–specific
primers were sense primer 59-TCCCATGAGATCGCTACAAAC-39
and antisense primer 59-TGATAATGGTTCTTGGCCTCT-39; mu-
rine SAP mRNA–specific primers were sense primer 59-
CTTCACCAGCCTTCTTTCAGA-39 and antisense primer 59-
ACGGACTGTGACTTTTGATTGT-39; and b-actin–specific
primers were sense primer 59-TAAAACGCAGCTCAGTAACA-
GTCCG-39 and antisense primer 59-TGCAATCCTGTGGCAT-
CCATGAAAC-39. After separation on a 1.5% agarose gel, band
proportions were estimated by measuring the intensity of ethidium
bromide fluorescence with a digital camera (Imagemaster VDS,
Pharmacia) by using commercial gel analysis software (Sigma Gel,
SPSS).
Statistics
Data are expressed as mean6SEM, and statistical analysis was
performed by Student t test. A value of P,0.05 was taken to denote
statistical significance.
Results
AGP and AAT Reduce Early and Delayed
Apoptosis Induced by Renal I/R
Apoptosis contributes to I/R-induced organ dysfunction and
may serve as a target for the protective effects of acute phase
proteins. No apparent internucleosomal DNA cleavage was
detected at 2 hours of reperfusion in kidneys obtained from
mice treated with either AGP or AAT compared with kidneys
obtained from PBS-treated mice (Figure 1). These early
effects of AGP and AAT suggest direct inhibition of apopto-
sis, inasmuch as early primary apoptosis precedes the first
signs of inflammation in this model.2 In line, as indicated by
the absence of apparent internucleosomal DNA cleavage
(Figure 1), decreased numbers of TUNEL-positive nuclei
(Figure 2), and attenuated caspase-1– and caspase-3–like
activities (Figure 3), apoptosis was reduced after 24 hours in
mice treated with either AGP or AAT compared with PBS-
treated control mice, possibly because of a combination of
antiapoptotic and anti-inflammatory effects.
We previously demonstrated that inhibition of early apo-
ptosis prevents the initiation of inflammation as well as
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secondary apoptosis caused by inflammation in our model.1
The present study indicates that abrogation of inflammation
does not occur when apoptosis inhibitors are administered
after 2 hours of reperfusion. Hence, apoptosis precedes the
inflammatory response at 2 hours of reperfusion. Therefore,
administration of AGP or AAT at 2 hours of reperfusion
enabled us to differentiate primary apoptosis from secondary
apoptosis and to study the possible involvement of an
anti-inflammatory effect of these acute phase proteins. Com-
pared with PBS treatment, AAT administered at 2 hours of
reperfusion decreased caspase-1– and caspase-3–like activi-
ties after 24 hours of reperfusion (Figure 3). However, AAT
did not reduce internucleosomal DNA cleavage (Figure 1),
whereas AGP reduced caspase-1– and caspase-3–like activi-
ties (Figure 3) and prevented internucleosomal DNA cleav-
age after 24 hours (Figure 1). These data suggest that reduced
secondary apoptosis is a result of the anti-inflammatory effect
of AGP and AAT, although we cannot exclude a contribution
via direct inhibition of secondary apoptosis.
To investigate the therapeutic efficacy of AGP treatment,
the effect of a dose range of AGP on internucleosomal DNA
cleavage after 2 hours of reperfusion was studied. A single
dose of 1.7 mg AGP at reperfusion sufficed to reduce renal
internucleosomal DNA cleavage (Figure 1). This therapeutic
effect gradually declined when dosages of 0.5 of 0.17 mg of
AGP were used (Figure 1). Rodent acute phase plasma has
been reported to contain up to 3.5 mg/mL AGP compared
with almost undetectable constitutive levels,10 indicating that
systemic rises in endogenous AGP during an APR are
potentially protective against I/R-induced apoptosis.
AGP and AAT Reduce Inflammation After I/R
We studied the effects of AGP and AAT on I/R-induced
inflammation by assessing renal TNF-a expression and neu-
trophil influx. At 24 hours after I/R, AGP and AAT admin-
istered at reperfusion limited TNF-a expression (Figure 5D
and 5E) and neutrophil influx (Figure 4). These effects are
most likely the result of direct inhibition of early primary
apoptosis, implicated in the subsequent induction of inflam-
mation.1 Alternatively, direct anti-inflammatory effects may
also be involved. Nevertheless, these findings explain the
Figure 1. Renal apoptosis is reflected by fragmented DNA
amplified by ligase-mediated polymerase chain reaction and
visualized on ethidium bromide–stained gel. In PBS-treated ani-
mals, internucleosomal DNA cleavage became apparent after 2
hours of reperfusion. Treatment with AGP or AAT prevented
internucleosomal DNA cleavage, except for AAT administered
after 2 hours of reperfusion. M indicates molecular weight mark-
ers (range, 100 to 2000 bp).
Figure 2. Representative light micrographs showing evident in situ detection of DNA nick ends by TUNEL histology (magnification
3200). In contrast to cells from sham-operated mice (A), tubular epithelial cells of outer medulla of biopsies obtained from PBS-treated
mice after 24 hours of reperfusion showed extensive apoptosis coinciding with influx of inflammatory cells (B, upper left corner). Treat-
ment with AGP on reperfusion apparently decreased numbers of TUNEL-positive nuclei after 24 hours (C), similar to numbers associ-
ated with AAT treatment on reperfusion (D).
Figure 3. In homogenates of tissue obtained after 1 day of
reperfusion, renal caspase-like activities were determined kineti-
cally by fluorogenic substrate assay in which Ac-YVAD-amc
(caspase-1–like) or Ac-DEVD-amc (caspase-3–like) served as
substrates. Data are expressed as increase in fluorescence as a
function of time, normalized against data obtained from sham-
operated group. Groups with t52 on x-axis received treatment
after 2 hours of reperfusion. All other groups were treated on
reperfusion. Compared with PBS-treated group, all groups
showed significantly decreased caspase-like activities (P,0.05,
not indicated). Statistical significance compared with animals
that received similar treatment on reperfusion was denoted at
#P,0.05. Data are mean6SEM.
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observed inhibition of secondary apoptosis in mice treated at
reperfusion.
AGP and AAT given after 2 hours of reperfusion attenu-
ated the inflammation at 24 hours to a lesser extent than did
treatment given at reperfusion (Figure 4). However, treat-
ments at both time points decreased inflammation compared
with PBS treatment at 24 hours of reperfusion (Figure 4). The
PBS-treated control mice showed significant renal inflamma-
tion as reflected by TNF-a expression in the outer stripe of
the outer medulla, along the damaged tubular epithelium
(Figure 5B), and in infiltrating leukocytes (Figure 5C). Also,
significant renal neutrophil accumulation was reflected by an
enhanced MPO content (Figure 4) and evident accumulation
of Gr-1–positive cells (Figure 6). AGP and AAT adminis-
tered at 2 hours prevented inflammation as reflected by these
parameters, revealing a direct anti-inflammatory potential of
AGP and AAT.
AGP and AAT Prevent I/R-Induced
Renal Dysfunction
Renal dysfunction was reflected by increased BUN content
and serum creatinine levels after 24 hours of reperfusion
(Figure 7). Compared with PBS, both AGP and AAT admin-
istered at reperfusion lowered BUN content and serum
creatinine levels. However, compared with PBS, AGP and
AAT administered after 2 hours of reperfusion failed to
significantly decrease BUN or serum creatinine. These find-
ings illustrate the necessity for the prevention of primary
apoptosis-induced inflammation in addition to the direct
prevention of inflammation after I/R for optimal therapeutic
effects.
Renal I/R Induces an APR
To investigate whether renal I/R induces an APR, serum
SAP and AGP levels and hepatic acute phase protein
mRNA content were measured. SAP was used as a marker
for the APR because it is coreleased with AGP and AAT
during the APR. Renal I/R induced an elevation in plasma
Figure 4. Neutrophil influx was assessed quantitatively by
determination of MPO increase after 24 hours of reperfusion.
Values are presented relative to amount of MPO present in con-
tralateral kidney harvested immediately after reperfusion and
normalized with respect to MPO increase after 24 hours of
reperfusion in PBS-treated mice. The groups with t52 received
treatment after 2 hours of reperfusion. *P,0.05 vs control
treated animals; #P,0.05 vs animals that received similar treat-
ment on reperfusion. Data are mean6SEM.
Figure 5. Representative light micrographs showing immunohistochemical staining of TNF-a by
mAb 52B83 (magnification 3100). Although absent in kidneys obtained from sham-operated con-
trols (A), TNF-a was expressed in outer stripe of outer medulla and distributed in and along dam-
aged tubular epithelium (B) as well as in infiltrating leukocytes (C) after 24 hours of reperfusion.
Treatment with AGP on reperfusion decreased intrarenal TNF-a expression after 24 hours (D), simi-
lar to AAT treatment on reperfusion (E).
Figure 6. Representative light micrographs showing immunohis-
tochemical staining by mAb Gr-1 of infiltrating neutrophils (mag-
nification 3100). Neutrophils were scarce in kidneys obtained
from sham-operated animals (A). In contrast, marked renal neu-
trophil accumulation (B) was observed after 24 hours of
reperfusion.
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SAP levels at 16 and 24 hours after ischemia (Table). LPS
administration served as a positive control and increased
SAP levels after 36 hours. Serum AGP levels increased to
a similar extent (an approximate factor 10 compared with
constitutive levels) after 24 hours of reperfusion and 36
hours after LPS (data not shown). In contrast to previous
reports,9,10 our results show no apparent rise in hepatic
AAT mRNA levels after renal I/R or LPS administration
(Figure 8). Conversely, after 16 hours of reperfusion,
hepatic AGP and SAP mRNA levels increased compared
with levels in sham-operated control mice or mice that
received only PBS (Figure 8). This rise in hepatic acute
phase protein mRNA was similar to that observed in mice
16 hours after 30 mg LPS (Figure 8.). These data clearly
demonstrate that renal I/R induces an APR.
Discussion
The effects of the acute phase proteins AGP and AAT on
early (2-hour) and late (24-hour) apoptosis and inflammation
after renal I/R were investigated. Both AGP and AAT
administered at reperfusion decrease early as well as late
apoptosis, as reflected by renal internucleosomal DNA cleav-
age, TUNEL histology, and caspase-like activities. In line, we
previously demonstrated that abrogating acute early apoptosis
with selective antiapoptotic agents prevents subsequent in-
flammation as well as secondary apoptosis caused by inflam-
mation, whereas antiapoptotic treatment that is initiated after
the onset of apoptosis does not reduce I/R-induced inflam-
mation.1 In contrast, in the present study, treatment after 2
hours of reperfusion inhibited inflammation, which is sup-
ported by reports of anti-inflammatory effects mediated by
AGP and AAT.12,13
Early primary19,20 as well as late secondary2,21 apoptosis
after I/R has been reported to be caused by various means.
The present results, showing that AGP and (to a lesser extent)
AAT protect against TNF-a–dependent late apoptosis,2 are in
line with data from Van Molle et al.14 They showed that AGP
protects against TNF-a–induced liver apoptosis in both
galactosamine-pretreated and actinomycin D–pretreated
mice, whereas AAT conferred protection in only the galac-
tosamine model. Because inflammation is not involved in the
process of primary apoptosis after I/R, our results show that
the antiapoptotic potential of AGP and AAT is not limited to
TNF-a–induced apoptosis.
AGP has been reported to exhibit anti-inflammatory
properties, such as inhibition of neutrophil activation and
induction of macrophage-derived interleukin-1 receptor
antagonist release.11 AGP also binds to bacterial endotoxin
and protects mice from endotoxin-induced septic and
hypovolemic shock.22,23 Currently, no clear antiapoptotic
property can be deduced from the AGP molecule. AAT can
inhibit neutrophil superoxide production,24 induce macro-
phage-derived interleukin-1 receptor antagonist release,11
and reduce TNF-a–induced lethality.25 AAT additionally
inhibits elastase26 and, as a consequence, elastase-
dependent synthesis and release of platelet-activating fac-
tor,26 a mediator of I/R-induced inflammation.27 Elastase
has been reported to cleave tyrosyl-tRNA synthetase dur-
ing apoptosis to fragments with interleukin-8 –like chemo-
tactic properties,28 a process potentially involved in pri-
mary I/R-induced apoptosis.1 AGP or AAT may interact
with the proteolytic cascade of enzymes involved in
apoptosis. However, both acute phase proteins lack inhib-
itory effects on caspases in vitro (Dr C. Libert, personal
communication, 1999). Further studies are needed to
establish the molecular mechanisms by which AGP and
AAT prevent I/R-induced apoptosis and inflammation.
Antecedent ischemia can induce protection from I/R-
induced injury in a biphasic pattern.8 Such protection lasts
for 30 minutes to 2 hours and is followed by a second
window of protection appearing 12 to 24 hours later. This
so-called ischemic preconditioning has been attributed to
local protective mechanisms, including induction of heat-
shock proteins29 and adenosine formation.30 However,
brief ischemia in remote organs31,32 or endotoxin pretreat-
ment4 – 6 has been shown to confer similar protection,
suggesting involvement of other than local mechanisms.
Indeed, the observed I/R-induced SAP and AGP increase
and elevated hepatic acute phase protein mRNA content
Effects of I/R on Serum SAP Levels
Intervention
Time After
Intervention, h
Serum SAP,
mg/mL n
Renal I/R 8 25.868.1 6
Renal I/R 16 47.267.5 6
Renal I/R 24 127.4626.4 6
Sham I/R 24 28.466.3 3
30 mg LPS* 36 202.6636.3 3
PBS control 36 15.863.0 3
*In 0.5 mL IP PBS.
Figure 7. Renal function after 24 hours in different experi-
mental groups as reflected by BUN content (A) and serum
creatinine (B). Groups with t52 received treatment after 2
hours of reperfusion. *P,0.05 vs PBS-treated animals. Data
are mean6SEM.
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show that renal I/R induces an APR. Our data also indicate
that the serum AGP increase during the APR is of
potentially sufficient extent to protect against I/R-induced
apoptosis. Thus, an APR likely confers systemic protection
against I/R injury, which could contribute to the second
window of protection associated with ischemic
preconditioning.
The physiological mode of protection outlined above
may determine the natural history of clinical conditions
associated with I/R as observed during severe trauma or
septic shock. For instance, sepsis mortality is highest
during the initial stages of the disease, and the chances of
survival increase with disease duration.33 This increased
survival may well be a consequence of protection against
shocklike complications because systemic levels of acute
phase proteins increase as the disease progresses.34 More-
over, protective acute phase proteins such as AGP and
AAT may provide new means to treat clinical conditions
associated with I/R injury.
We conclude that the APR may be part of a physiolog-
ical protection mechanism against I/R injury and show that
protection conferred by acute phase proteins such as AGP
and AAT is mediated by distinct antiapoptotic as well as
anti-inflammatory effects. We additionally demonstrate
that I/R itself induces an APR, which may explain the
second window of protection induced by ischemic
preconditioning.
Acknowledgments
This study was supported by the Dutch Kidney Foundation (grant
C98.1719) and the European Community Biotechnology program
(grant PL962107). We thank Annemarie van Bijnen for expert
technical assistance.
References
1. Daemen MARC, Van ’t Veer C, Denecker G, et al. Inhibition of apoptosis
induced by ischemia-reperfusion prevents inflammation. J Clin
Invest. 1999;104:541–549.
2. Daemen MARC, Van de Ven WCM, Heineman E, et al. Pro- and
anti-inflammatory mechanisms in renal reperfusion injury in mice: mod-
ulation by endogenous tumor necrosis factor alpha and interleukin-10.
Transplantation. 1999;67:792–800.
3. Baumann H, Gauldie J. The acute phase response. Immunol Today.
1994;15:74–80.
4. Meng X, Ao L, Brown JM, et al. LPS induces late cardiac functional
protection against ischemia independent of cardiac and circulating TNF-
alpha. Am J Physiol. 1997;273:H1894–H1902.
5. Berg JT, Allison RC, Taylor AE. Endotoxin extends survival of adult
mice in hyperoxia. Proc Soc Exp Biol Med. 1990;193:167–170.
6. Heemann U, Szabo A, Hamar P, et al. Lipopolysaccharide pretreatment
protects from renal ischemia/reperfusion injury. Am J Pathol. 2000;156:
287–293.
7. Yamashita N, Hoshida S, Taniguchi N, et al. Whole-body hyperthermia
provides biphasic cardioprotection against ischemia/reperfusion injury in
the rat. Circulation. 1998;98:1414–1421.
8. Meldrum DR, Cleveland JJ, Rowland RT, et al. Early and delayed
preconditioning: differential mechanisms and additive protection. Am J
Physiol. 1997;273:H725–H733.
9. Yiangou M, Paraskeva E, Hsieh CC, et al. Induction of a subgroup of
acute phase protein genes in mouse liver by hyperthermia. Biochim
Biophys Acta. 1998;1396:191–206.
10. Schreiber G, Tsykin A, Aldred AR, et al. The acute phase response in the
rodent. Ann N Y Acad Sci. 1989;557:61–85.
11. Tilg H, Vannier E, Vachino G, et al. Anti-inflammatory properties of
hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1)
receptor antagonist over IL-1 beta synthesis by human peripheral blood
mononuclear cells. J Exp Med. 1993;178:1629–1636.
12. Williams JP, Weiser MR, Pechet TT, et al. Alpha 1-acid glycoprotein
reduces local and remote injuries after intestinal ischemia in the rat. Am J
Physiol. 1997;273:G1031–G1035.
13. Libert C, Vanmolle W, Brouckaert P, et al. Alpha(1)-antitrypsin inhibits
the lethal response to TNF in mice. J Immunol. 1996;157:5126–5129.
14. Van Molle W, Libert C, Fiers W, et al. Alpha(1)-acid glycoprotein and
alpha(1)-antitrypsin inhibit TNF-induced but not anti-FAS-induced apo-
ptosis of hepatocytes in mice. J Immunol. 1997;159:3555–3564.
15. Vercammen D, Beyaert R, Denecker G, et al. Inhibition of caspases
increases the sensitivity of L929 cells to necrosis mediated by tumor
necrosis factor. J Exp Med. 998;187:1477–1485.
16. Gavrieli Y, Sherman Y, Ben SS. Identification of programmed cell death
in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol.
1992;119:493–501.
17. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation
of antigens by single radial immunodiffusion. Immunochemistry. 1965;2:
235–254.
18. Prowse KR, Baumann H. Molecular characterization and acute phase
expression of the multiple Mus caroli alpha 1-acid glycoprotein (AGP)
genes: differences in glucocorticoid stimulation and regulatory elements
between the rat and mouse AGP genes. J Biol Chem. 1990;265:
10201–10209.
19. Lieberthal W, Menza SA, Levine JS. Graded ATP depletion can cause
necrosis or apoptosis of cultured mouse proximal tubular cells. Am J
Physiol. 1998;43:F315–F327.
20. Zager RA, Iwata M, Conrad DS, et al. Altered ceramide and sphingosine
expression during the induction phase of ischemic acute renal failure.
Kidney Int. 1997;52:60–70.
21. Nogae S, Miyazaki M, Kobayashi N, et al. Induction of apoptosis in
ischemia-reperfusion model of mouse kidney: possible involvement of
Fas. J Am Soc Nephrol. 1998;9:620–631.
Figure 8. Hepatic acute phase protein
mRNA expression 16 hours after either
renal I/R, sham operation, administration
of 30 mg of LPS IP, or PBS only. Shown
are representative samples, of which
cDNA was amplified in three 2-fold serial
dilutions and calibrated against identical
levels of b-actin mRNA. Band propor-
tions are indicated and expressed as
pixel units, calibrated according to raw
pixel values of the digital capture image.
Background (black) corresponds to a
pixel value of 0; amplified DNA (white)
corresponds to a pixel value of 255.
Daemen et al Acute Phase Proteins in I/R 1425
22. Moore DF, Rosenfeld MR, Gribbon PM, et al. Alpha-1-acid (AAG,
orosomucoid) glycoprotein: interaction with bacterial lipopolysaccharide
and protection from sepsis. Inflammation. 1997;21:69–82.
23. Muchitsch EM, Auer W, Pichler L. Effects of alpha 1-acid glycoprotein
in different rodent models of shock. Fundam Clin Pharmacol. 1998;12:
173–181.
24. Bucurenci N, Blake DR, Chidwick K, et al. Inhibition of neutrophil
superoxide production by human plasma alpha 1-antitrypsin. FEBS Lett.
1992;300:21–24.
25. Libert C, Brouckaert P, Fiers W. Protection by alpha 1-acid glycoprotein against
tumor necrosis factor-induced lethality. J Exp Med. 1994;180:1571–1575.
26. Camussi G, Tetta C, Bussolino F, et al. Synthesis and release of plate-
let-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or
alpha 1-antichymotrypsin and is stimulated by proteinases. J Exp Med.
1988;168:1293–1306.
27. Torras J, Bordalba JR, Seron D, et al. Protective effect of the PAF
antagonist BN 52021 in an experimental renal warm ischemia model.
Transpl Int. 1993;6:236–238.
28. Wkasugi K, Schimmel P. Two distinct cytokines released from a human
aminoacyl-tRNA synthetase. Science. 1999;284:147–150.
29. Kume M, Yamamoto Y, Saad S, et al. Ischemic preconditioning of the liver
in rats: implications of heat shock protein induction to increase tolerance of
ischemia-reperfusion injury. J Lab Clin Med. 1996;128:251–258.
30. Baxter GF, Marber MS, Patel VC, et al. Adenosine receptor involvement
in a delayed phase of myocardial protection 24 hours after ischemic
preconditioning. Circulation. 1994;90:2993–3000.
31. Verdouw PD, Gho BC, Koning MM, et al. Cardioprotection by ischemic
and nonischemic myocardial stress and ischemia in remote organs: impli-
cations for the concept of ischemic preconditioning. Ann N Y Acad Sci.
1996;793:27–42.
32. Gho BC, Schoemaker RG, Van den Doel DM, et al. Myocardial pro-
tection by brief ischemia in noncardiac tissue. Circulation. 1996;94:
2193–2200.
33. Rangel FM, Pittet D, Hwang T, et al. The dynamics of disease pro-
gression in sepsis: Markov modeling describing the natural history and
the likely impact of effective antisepsis agents. Clin Infect Dis. 1998;27:
185–190.
34. Dominioni L, Dionigi R, Zanello M, et al. Sepsis score and acute-phase
protein response as predictors of outcome in septic surgical patients. Arch
Surg. 1987;122:141–146.
1426 Circulation September 19, 2000
